Veracyte Total Assets 2012-2024 | VCYT
Veracyte total assets from 2012 to 2024. Total assets can be defined as the sum of all assets on a company's balance sheet.
| Veracyte Annual Total Assets (Millions of US $) |
|
|---|---|
| 2024 | $1,300 |
| 2023 | $1,115 |
| 2022 | $1,156 |
| 2021 | $1,188 |
| 2020 | $457 |
| 2019 | $275 |
| 2018 | $121 |
| 2017 | $79 |
| 2016 | $101 |
| 2015 | $75 |
| 2014 | $65 |
| 2013 | $80 |
| 2012 | $19 |
| 2011 | $10 |
| Veracyte Quarterly Total Assets (Millions of US $) |
|
|---|---|
| 2024-12-31 | $1,300 |
| 2024-09-30 | $1,275 |
| 2024-06-30 | $1,234 |
| 2024-03-31 | $1,200 |
| 2023-12-31 | $1,115 |
| 2023-09-30 | $1,125 |
| 2023-06-30 | $1,161 |
| 2023-03-31 | $1,157 |
| 2022-12-31 | $1,156 |
| 2022-09-30 | $1,126 |
| 2022-06-30 | $1,144 |
| 2022-03-31 | $1,174 |
| 2021-12-31 | $1,188 |
| 2021-09-30 | $1,186 |
| 2021-06-30 | $1,027 |
| 2021-03-31 | $1,025 |
| 2020-12-31 | $457 |
| 2020-09-30 | $454 |
| 2020-06-30 | $257 |
| 2020-03-31 | $267 |
| 2019-12-31 | $275 |
| 2019-09-30 | $260 |
| 2019-06-30 | $252 |
| 2019-03-31 | $124 |
| 2018-12-31 | $121 |
| 2018-09-30 | $119 |
| 2018-06-30 | $65 |
| 2018-03-31 | $71 |
| 2017-12-31 | $79 |
| 2017-09-30 | $84 |
| 2017-06-30 | $88 |
| 2017-03-31 | $93 |
| 2016-12-31 | $101 |
| 2016-09-30 | $70 |
| 2016-06-30 | $75 |
| 2016-03-31 | $84 |
| 2015-12-31 | $75 |
| 2015-09-30 | $81 |
| 2015-06-30 | $83 |
| 2015-03-31 | $55 |
| 2014-12-31 | $65 |
| 2014-09-30 | $72 |
| 2014-06-30 | $68 |
| 2014-03-31 | $72 |
| 2013-12-31 | $80 |
| 2013-09-30 | $24 |
| 2013-06-30 | $27 |
| 2013-03-31 | $0 |
| 2012-12-31 | $0 |
| 2012-09-30 | $0 |
| 2012-06-30 | $0 |
| 2011-12-31 | $10 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED INSTRUMENTS | $2.327B | $0.446B |
| Veracyte, Inc. is a diagnostics company. It is focused on discovering, developing and commercializing molecular cytology solutions. The Company provides Afirma Thyroid FNA Analysis, which helps physicians in reducing unnecessary diagnostic surgeries for patients with thyroid nodules. Veracyte is also developing Afirma Malignant GEC test. It serves endocrinologists, radiologists, and head and neck specialists. Veracyte, Inc. is headquartered in South San Francisco, California. | |||